| Name | Title | Contact Details |
|---|
Pickleball is a journey. Let us meet you where you are. Whether youre just getting started or have been playing for years, weve got you covered with the paddles, accessories, apparel, footwear, and more to help you play your best. Our trusted experts have your back. We love this game. With a history that spans almost as long as the sport itself, we proudly stand on a mission to provide expert-approved gear––selected by players, for players. More than just shopping. * Helpful product selection quizzes * 30-Day Paddle Test Drive Policy * Loyalty Rewards Program * Expert tips, tricks, and product reviews * Unrivaled customer service * Free balls with paddle purchase* *some exclusions apply Please contact us with any questions at (888) 854-0163. We know it can be hard to choose a pickleball paddle and our knowledgeable customer service experts are ready to help. With our Risk-Free 30-Day Paddle Return Policy, you can try a paddle for 30 days and if its not the right paddle for you, return it for exchange or full refund.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.